These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19488755)

  • 21. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.
    Nakagawa H; Saito H; Ikegami Y; Aida-Hyugaji S; Sawada S; Ishikawa T
    Cancer Lett; 2006 Mar; 234(1):81-9. PubMed ID: 16309825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.
    Duan JX; Cai X; Meng F; Sun JD; Liu Q; Jung D; Jiao H; Matteucci J; Jung B; Bhupathi D; Ahluwalia D; Huang H; Hart CP; Matteucci M
    J Med Chem; 2011 Mar; 54(6):1715-23. PubMed ID: 21341674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Properties of Ultraviolet Exposed Camptothecin Studied by Using Optical Spectroscopy Methods.
    Ziomkowska B; Wybranowski T; Cyrankiewicz M; Kruszewski S
    Comb Chem High Throughput Screen; 2016; 19(4):319-24. PubMed ID: 26953237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
    Pick A; Müller H; Wiese M
    Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
    Singh MS; Juvale K; Wiese M; Lamprecht A
    Eur J Pharm Sci; 2015 Sep; 77():1-8. PubMed ID: 25976226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
    Marighetti F; Steggemann K; Hanl M; Wiese M
    ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
    Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
    Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
    Guo S; Zhang X; Gan L; Zhu C; Gan Y
    J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3D-QSAR study of 20 (S)-camptothecin analogs.
    Lu AJ; Zhang ZS; Zheng MY; Zou HJ; Luo XM; Jiang HL
    Acta Pharmacol Sin; 2007 Feb; 28(2):307-14. PubMed ID: 17241535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
    Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
    Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
    Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
    Zhang S; Yang X; Coburn RA; Morris ME
    Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.